Healthcare / BiotechnologyTaipei Exchange
$20.25
+0.35 (+1.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $370.7M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
11.8x
↓EV/EBITDA
8.9x
↓ROE
14.2%
↑Gross Margin
35.2%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.7%
FCF CAGR
—
FCF margin
-13.7%
FCF / Net income
-0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.20B · net income $537.4M · FCF $-164.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.20B | $1.20B | $1.22B | $1.05B | $1.27B |
| Net Income | $537.4M | $537.4M | $182.4M | $30.0M | $36.4M |
| EBITDA | $631.6M | $631.6M | $313.8M | $219.6M | $260.7M |
| EPS | — | — | 0.57 | 0.09 | 0.11 |
| Gross Margin | 35.2% | 35.2% | 28.5% | 21.0% | 10.3% |
| Operating Margin | 16.5% | 16.5% | 9.8% | -0.4% | -7.4% |
| Net Margin | 44.7% | 44.7% | 15.0% | 2.9% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.08 | 0.24 |
| Current Ratio | 3.96 | 3.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-164.3M | $-164.3M | $399.9M | $370.7M | $547.6M |
| Returns | |||||
| ROE | 14.2% | 14.2% | 5.2% | 0.9% | 1.1% |
| Valuation | |||||
| P/E | 11.84 | 11.84 | 37.28 | 253.33 | 202.27 |
| EV/EBITDA | 8.94 | 8.94 | 17.78 | 31.46 | 25.97 |
| P/B | 1.66 | 1.66 | 1.93 | 2.30 | 2.10 |
| Growth & Yield | |||||
| Revenue Growth | -1.3% | -1.3% | 15.9% | -17.0% | — |
| EPS Growth | — | — | 533.3% | -18.2% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.57 → n/d
Residual
-5.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.